Program

View the IVHEM 2016 program below:

Friday 2 December

13.00hOpening of the workshop
by the Workshop Chairs
13.15hOpening lecture on WHO programs
Gottfried Hirnschall

Head, HIV/Viral Hepatitis Department
World Health Organization, USA
 
  Session 1: Results of National programs: Barriers & Successes
13.45hNational perspectives in Europe - common themes and challenges
Angelos Hatzakis
Professor of Epidemiology and Preventive Medicine
Athens University Medical School, Athens Greece
Co-Chair, Hepatitis B and C Public Policy Association
14.15hNational Programs - the Netherlands
Anouk Urbanus

‎Policy Advisor Infectious Diseases
National Institute of Public Health and the Environment, Bilthoven, the Netherlands
14.30hNational Programs - Egypt
Wahid Doss 
Professor, Cairo University, Cairo, Egypt
Head, National Committee for Control of Viral Hepatitis, Egypt
 14.45hNational Programs - Australia
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
15.00hNational Programs - US
John Ward
Director, Viral Hepatitis Program
Centers of Disease Control and Prevention, Atlanta, USA
15.15hDiscussion
 
15.45hGroup Picture
 
16.00hCoffee Break
 
  Session 2: Progress towards elimination - Specific Populations
16.30hProgress towards elimination in the Australian prison sector
Andrew Lloyd 
Infectious Diseases Physician & Prisoner Health Researcher
Kirby Institute, University of New South Wales, and Justice Health & Forensic Mental Health Network, Sydney, Australia
16.50hChildren & Pregnant women
Manal El-Sayed
Professor of Pediatrics
Ain Shams University, Cairo, Egypt
17.10hPeople who inject drugs
Olav Dalgard
Professor of Infectious Diseases
Akershus University Hospital, Lørenskog, Norway
17.30hDiscussion
 
18.00hEnd of Day 1
A Networking reception and Workshop dinner are organized after the last session.
 

Saturday 3 December

  Session 3: Diagnosing
08.30hWHO Guidelines and Policies of testing
Margaret Hellard
Head, Centre for Population Health
Burnet Institute, Melbourne, Australia
08.50hProgess in testing technologies
Dmytro Donchuk
Infectious Diseases Specialist, HIV, TB and Viral Hepatitis Adviser
Médecins Sans Frontières, Brussels, Belgium
09.10hChallenges in Monitoring (POC)
Isabelle Andrieux-Meyer
HIV/HCV Team Lead
Drugs for Neglected Diseases initiative, Frontières, Geneva, Switzerland
09.30hChallenges in regards to resistance
Mark Nelson
Consultant Physician
Chelsea and Westminster Hospital, London, United Kingdom
09.50hDiscussion
 
10.00hCoffee Break
 
  Session 4: Reducing Transmission and harm
10.30hGlobal Injection Safety Campaign and Prevention Strategies
Arshad Altaf 

Consultant Injection Safety
World Health Organization, Geneva, Switzerland
10.50hCan we afford not to treat reinfection 
Peter Vickerman
Professor of Infectious Disease Modelling
University of Bristol, Bristol, United Kingdom
11.10hCreating awareness and sharing the knowledge
Anya Sarang
Director
Andrey Rylkov Foundation for Health and Social Justice, Moscow, Russia
11.30hCommunity and harm reduction response to infection and reinfection
Eberhard Schatz
Coordinator European Initiative on Hepatitis C and Drug Use
Correlation Network c/o Foundation De Regenboog Groep, Amsterdam, the Netherlands
11.50hDiscussion
 
12.15hLunch
 
  Session 5: Future scenarios for elimination
13.15hVaccine development and results
Andrea Cox 
Professor of Medicine
Johns Hopkins School of Medicine Baltimore, MD, USA
13.35hMinimising treatment duration and doses
Jordan Feld
Research Director and Clinician-Scientist
Toronto Centre for Liver Disease, Toronto, Canada
13.55hRole of generic drugs
Andrew Hill
Senior Visiting Research Fellow
Liverpool University, Liverpool, UK
14.15hFinancial models for high- and low income countries
Pieter Walhof
Director PharmAccess and Health Insurance Fund
PharmAccess Foundation, Amsterdam, the Netherlands

14.35hBuilding global capacity
Stefano Vella
Chair of Global Health
Istituto Superiore di Sanità
 
14.55hRound table Discussion
 
15.30hProgram adjournment